The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | The importance of del(17p) as a prognostic factor in myeloma
In this video, Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, discusses the importance of del(17p) as a poor prognostic factor in multiple myeloma, and compares this to the prognostic value of patients with t(4;14). Dr Corre also discusses two important details to consider with these genomic aberrations: the clonal size of del(17p) and the possibility of TP53 mutation resulting in double-hit myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
